BiomX Inc.
ASE: PHGELive Quote
📈 ZcoreAI Score
Our AI model analyzes BiomX Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PHGE Z-Score →About BiomX Inc.
Healthcare
Biotechnology
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
📊 Fundamental Analysis
BiomX Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -316.9%, which indicates that capital utilization is currently under pressure.
At a current price of $2.89, PHGE currently trades near the bottom of its 52-week range (11%), indicating potential value or weakness (Range: $1.50 - $14.71).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$18.91M
Trailing P/E
--
Forward P/E
-0.22
Beta (5Y)
1.70
52W High
$14.71
52W Low
$1.50
Avg Volume
1.04M
Day High
Day Low